Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CR-50 is an antibody designed to therapeutically inhibit Reelin, a large extracellular glycoprotein. Reelin plays critical roles in neuronal development and synaptic plasticity in the central nervous system, and also in non-neuronal functions such as promoting endothelial-leukocyte adhesion in inflammation. CR-50 works by interfering with Reelin's homopolymerization and signaling, particularly through its N-terminal region, which is critical for efficient signal transduction and multimer formation. This inhibition aims to reduce inflammation, leukocyte infiltration, and pannus formation in autoimmune diseases, and to modulate neuronal processes in neurological conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CR-50.